AIM
SAGE

Advantage Investment Management’s Sage Therapeutics SAGE Stock Holding History

Advantage Investment Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-13
Closed -$2K – 1053
2017
Q4 		$2K Buy
+13
New +$1.26K ﹤0.01% 929

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Advantage Investment Management's SAGE Position: Q1 2018 in Review

Advantage Investment Management sold out of Sage Therapeutics (SAGE) in Q1 2018, closing a stake of 13 shares — an estimated $2K sold.

Advantage Investment Management first reported a position in SAGE in Q4 2017 and held it in 1 quarter. The position peaked at $2K in Q4 2017. 250 funds tracked by Wall St. Rank hold SAGE as of Q1 2018.

  • Advantage Investment Management reported no remaining Sage Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Advantage Investment Management sold 13 Sage Therapeutics shares in Q1 2018, an estimated $2K.
  • Advantage Investment Management first reported a position in Sage Therapeutics in Q4 2017 and held it in 1 quarter.
  • Advantage Investment Management's Sage Therapeutics position peaked at $2K in Q4 2017.
  • 250 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2018.

Based on Advantage Investment Management's 13F filing for Q1 2018, filed 15 May 2018.